Biology of Blood and Marrow Transplantation
Volume 13, Issue 10 , Pages 1121-1134 , October 2007

Second Malignancies after Allogeneic Hematopoietic Cell Transplantation

  • Thomas Lowe

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests: Thomas Lowe, MD, City of Hope Comprehensive Cancer Center, Division of Medical Oncology and Therapeutics Reasearch, 1500 East Duarte Road, Duarte, CA 91010.
    • ,
  • Smita Bhatia
    • ,
  • George Somlo

Received 28 February 2007 ,Accepted 6 July 2007.

References 

  1. Cancer survivors: living longer, and now, better. [editorial] Lancet. 2004;364:2153–2154
  2. Rowland J, Mariotto A, Aziz N, Tesauro G, Feuer EJ. Cancer survivorship—United States, 1971-2001. MMWR Morb Mortal Wkly Rep. 2004;53:526–529
  3. Atlas LD. The National Marrow Donor Program in 2006: constants and challenges. Transfusion. 2006;46:1080–1084
  4. Ries LAG, Harkins D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute (http://seer.cancer.gov/csr/1975_2003/), based on November 2005 SEER data submission, posted to the SEER Web site, 2006.
  5. Neugut AI, Meadows AT, Robinson E. Introduction. In:  Neugut AI,  Meadows AT,  Robinson E editor. Multiple Primary Cancers. Philadelphia, PA: Lippincott Williams and Wilkins; 1999;p. 1–12
  6. Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors (Report 13: solid cancer and noncancer disease mortality: 1950-1997). Radiat Res. 2003;160:381–407
  7. Inskip PD. Second cancers following radiotherapy. In:  Neugut AI,  Meadows AT,  Robinson E editor. Multiple Primary Cancers. Philadelphia, PA: Lippincott Williams and Wilkins; 1999;p. 91–135
  8. Tucker MA, D’Angio GJ, Boice JD, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317:588–593
  9. UNSCEAR. Sources and Effects of Ionizing Radiation: United Nations Scientific Committee on the Effects of Atomic Radiation 2000 Report to the General Assembly, with Scientific Annexes, Vol II: Effects. New York: United Nations; 2000;
  10. Vega-Stromberg T. Chemotherapy-induced secondary malignancies. J Infus Nurs. 2003;26:353–361
  11. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst. 1995;87:524–530
  12. Pedersen-Bjergaard J, Ersboll J, Hansen VL, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide or non-Hodgkin’s lymphoma. N Engl J Med. 1988;318:1028–1032
  13. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med. 1996;334:745–751
  14. Boivin JF, Hutchison GB, Zauber AG. Incidence of second cancers in patients treated for Hodgkin’s disease. J Natl Cancer Inst. 1995;87:732–741
  15. Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries (The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries). Int J Cancer. 2000;88:672–678
  16. Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer. 1987;56:339–347
  17. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93:618–629
  18. Van Leeuwen FE, Klokman WJ, Stovall M, et al. The role of radiation dose, chemotherapy, treatment-related ovarian ablation, and other risk factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst. 2003;95:971–980
  19. Van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487–497
  20. Aisenberg AC, Finkestein DM, Doppke KP, Koerner FC, Boivin F, Willett CG. High risk of breast cancer after irradiation of young women with Hodgkin’s disease. Cancer. 1997;79:1203–1210
  21. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer. 1993;85:25–31
  22. Gallagher G, Forrest DL. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer. 2007;109:84–92
  23. Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006;24:1119–1126
  24. Hasegawa W, Pond GR, Rifkind JT, et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2005;35:51–55
  25. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21:1352–1358
  26. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19:464–471
  27. Socie G, Curtis RE, Deeg HJ. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18:348–357
  28. Kolb HJ, Socie G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation (Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group). Ann Intern Med. 1999;131:738–744
  29. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–2216
  30. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood. 1998;91:1833–1844
  31. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904
  32. Bhatia S, Ramsay LL, Steinbuch M, et al. Malignant neoplasms, following bone marrow transplantation. Blood. 1996;87:3633–3639
  33. Deeg HJ, Socie G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386–392
  34. Witherspoon RP, Deeg HJ, Storb R. Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplantation. 1994;57:1413–1418
  35. Pierga JY, Socie G, Gluckman E, et al. Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation. Radiother Oncol. 1994;30:55–58
  36. Lowsky R, Lipton J, Fyles G, et al. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol. 1994;12:2187–2192
  37. Deeg HJ, Witherspoon RP. Risk factors for the development of secondary malignancies after marrow transplantation. Hematol Oncol Clin North Am. 1993;7:417–429
  38. Witherspoon RP, Storb R, Pepe M, et al. Cumulative incidence of second malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone. Blood. 1992;79:289–290
  39. Kolb HJ, Guenther W, Duell T, et al. Cancer after bone marrow transplantation. Bone Marrow Transplant. 1992;10:135–138
  40. Socie G, Henry-Amar M, Cosset JM, Devergie A, Girinsky T, Gluckman E. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood. 1991;78:277–279
  41. Lishner M, Patterson B, Kandel R, et al. Cutaneous and mucosal neoplasms in bone marrow transplant recipients. Cancer. 1990;65:473–476
  42. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med. 1989;321:784–789
  43. Shapiro RS, McClain K, Frizzera G, et al. Ebstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71:1234–1243
  44. Deeg HJ, Sanders J, Martin P, et al. Secondary malignancies after marrow transplantation. Exp Hematol. 1984;12:660–666
  45. Penn I, Hammon W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc. 1969;1:106–112
  46. McKhann CF. Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation. 1969;8:209–212
  47. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis. 2001;3:70–78
  48. Orazi A, Hromas RA, Neiman RS, et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol. 1997;107:419–429
  49. Hoover RN. Lymphoma risks in populations with altered immunity—a search for mechanism. Cancer Res. 1992;52:5477s
  50. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore). 1991;70:137–160
  51. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998;338:1413–1421
  52. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg. 1988;25:367–472
  53. Lebland V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol. 1998;16:2052–2059
  54. Barker JN, Martin PL, Coad JE, et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant. 2001;7:395–399
  55. Gong JZ, Bayerl MG, Sandhaus LM, et al. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Am J Surg Pathol. 2006;30:328–336
  56. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108:2874–2880
  57. Snyder MJ, Stenzel TT, Buckley PJ, et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol. 2004;28:794–800
  58. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res. 1987;41:4262–4279
  59. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disroders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol. 1988;133:173–192
  60. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplant lymphoproliferative disorders. Blood. 1995;85:552–565
  61. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol. 1997;14:8–14
  62. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. World Health Organization Classification of Tumours. vol. 3:Lyon, France: IARC Press; 2001;p. 264–269
  63. Gross T, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant. 1999;23:251–258
  64. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant. 2004;10:59–65
  65. Preiksaitis JK. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis. 2004;39:1016–1023
  66. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation. 1985;39:461–472
  67. Cohen JI. Epstein-Barr virus lymphoproliferative disease associated with acquired immune deficiency. Medicine. 1991;70:137–160
  68. Henle G, Henle W. The virus as the etiologic agent of infectious mononucleosis. In:  Epstein MA,  Achong BG editor. The Epstein-Barr Virus. New York: Springer-Verlag; 1979;p. 297–320
  69. Wallace LE, Rickinson AB, Rowe M, Epstein MA. Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature. 1982;297:413–415
  70. Pearson GR, Orr TW. Antibody-dependent lymphocyte cytotoxicity against cells experiencing Epstein-Barr virus antigens. J Natl Cancer Inst. 1986;56:485–488
  71. Blazar BA, Patarroyo M, Klein E, Klein G. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate. J Exp Med. 1980;151:614–627
  72. Mathur A, Kamat DM, Filipovich AH, et al. Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders. Transplantation. 1994;57:1042–1045
  73. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71:1234–1243
  74. Andreone P, Gramenzi A, Lorenzini S, et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med. 2003;163:1997–2004
  75. Qu L, Xu S, Rowe D, Triulzi D. Efficacy of Epstein-Barr virus removal by leukoreduction of red blood cells. Transfusion. 2005;45:591–595
  76. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364–4369
  77. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539–546
  78. Lin JC, Smith MC, Pagano JS. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine against replication of Epstein-Barr virus. J Virol. 1984;50:50–55
  79. Keay S, Oldach D, Wiland A, et al. Post-transplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients. Clin Infect Dis. 1998;26:596–600
  80. Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL. Antiviral prophylaxis and the Epstein-Barr virus-related post-transplant lymphoproliferative disorders. Clin Transplant. 1995;9:53–59
  81. Darenkov IA, Macarelli MA, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation. 1997;64:848–852
  82. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med. 1996;154:1712–1717
  83. Kuo PC, Dafoe DC, Alfrey EJ, Sibley RK, Scandling JD. Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation. 1995;59:135–138
  84. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005;5:2894–2900
  85. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549–1555
  86. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99:2592–2598
  87. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95:807–814
  88. Mourad WA, Tulabah A, Al Sayed A, et al. The impact of the World Health Organization classification and clonality assessment of posttransplant lymphoproliferative disorders on disease management. Arch Pathol Lab Med. 2006;130:1649–1653
  89. Pitman SD, Huang Q, Zuppan CW, et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol. 2006;30:470–476
  90. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer. 2005;104:1661–1667
  91. Codeluppi M, Cocchi S, Guaraldi G, et al. Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: report of three cases. Transplant Proc. 2005;37:2634–2635
  92. Zhu K, Chen J, Chen S. Treatment of Epstein-Barr virus-associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review. Hematology. 2005;10:365–370
  93. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005;5:2901–2906
  94. Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation. 2005;80:1692–1698
  95. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6:569–576
  96. Pakakasama S, Eames GM, Morriss MC, et al. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004;78:755–757
  97. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360:436–442
  98. Durandy A. Anti-B and anticytokine therapy for the treatment of posttransplant lymphoproliferative disorder: past, present, and future. Transpl Infect Dis. 2001;3:104–107
  99. Haddad E, Paczesny S, Leblond V, et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood. 2001;97:1590–1597
  100. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol. 2003;21:897–906
  101. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12:2527–2534
  102. Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 1994;12:2535–2542
  103. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95:1588–1593
  104. Micallef INM, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18:947–955
  105. Milligan DW, Ruiz de Elvira MC, Kolb H-J, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT-EBMT Lymphoma and Late Effects Working Parties. Br J Haematol. 1999;106:1020–1026
  106. Tam CS, Seymour JF, Prince HM, et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica. 2006;91:1546–1550
  107. Fialkow PJ, Thomas ED, Bryant JI, Neiman PE. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet. 1971;1:251–255
  108. Cornelius EA. Rapid viral induction of murine lymphomas in the graft-versus-host reaction. J Exp Med. 1972;136:1533–1544
  109. Schwartz RS. Immunoregulation, oncogenic viruses, and malignant lymphomas. Lancet. 1972;1:1266–1269
  110. Gleichmann E, Melief CJ, Gleichmann H. Lymphomagenesis and autoimmunization caused by reactions of T-lymphocytes to incompatible structures of the major histocompatibility complex: a concept of pathogenesis. (review) Rec Results Cancer Res. 1978;64:292–315
  111. Thomas ED, Bryant JI, Buckner CD, et al. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet. 1972;1:1310–1313
  112. Cornelius EA. Rapid immunological induction of murine lymphomas: evidence for a viral etiology. Science. 1972;177:524–525
  113. Katz F, Reeves BR, Alexander S, Kearney L, Chessells J. Leukaemia arising in donor cells following allogeneic bone marrow transplantation for beta thalassaemia demonstrated by immunological, DNA and molecular cytogenetic analysis. Br J Haematol. 1993;85:326–331
  114. Brown SA, Bashey A, Schey SA. Donor cell leukaemia—an unresolved problem. Eur J Haematol. 1995;54:198–199
  115. Niederwieser DW, Appelbaum FR, Gastl G, et al. Inadvertent transmission of a donor’s acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med. 1990;322:1794–1796
  116. Bodo I, Peters M, Radich JP, et al. Donor-derived acute promyelocytic leukemia in a liver-transplant recipient. N Engl J Med. 1999;341:807–813
  117. Au WY, Pang A, Chan EC, Chu KM, Shek TW, Kwong YL. Epstein-barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation. Gastroenterology. 2005;129:2058–2063
  118. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol. 2006;16:83–97
  119. Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 2.0, March 2006. (www.survivorshipguidelines.org) [accessed May 19, 2007].

PII: S1083-8791(07)00349-7

doi: 10.1016/j.bbmt.2007.07.002

Biology of Blood and Marrow Transplantation
Volume 13, Issue 10 , Pages 1121-1134 , October 2007

Article Tools